The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Open accessAbstract
Cyclin-dependent kinase 9 (CDK9), an important regulator of transcriptional elongation, is a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation. We characterized NVP-2, a selective ATP-competitive CDK9 inhibitor, and THAL-SNS-032, a selective CDK9 degrader consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN). To our surprise, THAL-SNS-032 induced rapid degradation of CDK9 without affecting the levels of other SNS-032 targets. Moreover, the transcriptional changes elicited by THAL-SNS-032 were more like those caused by NVP-2 than those induced by SNS-032. Notably, compound washout did not significantly reduce levels of THAL-SNS-032-induced apoptosis, suggesting that CDK9 degradation had prolonged cytotoxic effects compared with CDK9 inhibition. Thus, our findings suggest that thalidomide conjugation represents a promising strategy for converting multi-targeted inhibitors into selective degraders and reveal that kinase degradation can induce distinct pharmacological effects compared with inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several mechanisms have been shown to contribute to this increase in selectivity. This includes steric incapability of some targets to form a productive ternary complex, or lack of a suitably positioned lysine residue for ubiquitination.62−69”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [64]
In the citing paper
“Similarly, because of a non-linear dependence on binding, degradation target profiles often differ vastly from parental inhibitor selectivity profiles (Olson et al., 2018)”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Olson et al., 2018
In the citing paper
“It is widely believed that degraders uncouple efficacy from target occupancy (Gadd et al., 2017; Nowak et al., 2018; Olson et al., 2018; Roy et al., 2019).”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Olson et al., 2018
In the citing paper
“Simultaneously, it led to a marked sensitization (15-fold shift in EC50) to the CDK9-targeting PROTAC THAL-SNS-03240 (Extended Data Fig. 6B and C).”
From Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders (2023) · cites this paper as [40]
In the citing paper
“For example, selective degradation of CDK9 was achieved by converting the non-selective CDK inhibitor SNS-032 into a degrader[9].”
From Development of dual and selective degraders of cyclin-dependent kinases 4 and 6 (2019) · cites this paper as [9]
In the citing paper
“It has further been shown that PROTAC selectivity does not necessarily mimic that of its target-binding warhead, but rather depends sensitively on the linker 20, 23, 24, 33”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [24]
In the citing paper
“and can have a duration of action that extends beyond clearance and depends on the turnover rate of the protein target rather than residence time 23,24,25 .”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [23]
In the citing paper
“Regarding clinical applications, appropriate dosage may be an issue, as saturating doses of free PROTAC molecules can antagonize the binding of binary PROTAC-protein complexes to their ternary partner and abrogate catalytic degradation, a well-documented phenomenon known as the hook effect in cell assays 23,33,34 .”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells
Boyer, L. A., Lee, T. I., Cole, M. F., Johnstone, S. E., Levine, S. S., Zucker, J. P., Guenther, M. G., Kumar, R. M., Murray, H. L., Jenner, R. G., et al. (2005) · Cell · doi:10.1016/j.cell.2005.08.020 · Cited by 4,505
Self-citationPhthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Self-citationMalumbres, M. (2014) · Genome biology · doi:10.1186/gb4184 · Cited by 1,730
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Lin, C. Y., Lovén, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.08.026 · Cited by 1,543
Self-citationc-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
Self-citationMcAlister, G. C., Nusinow, D. P., Jedrychowski, M. P., Wühr, M., Huttlin, E. L., Erickson, B. K., Rad, R., Haas, W., & Gygi, S. P. (2014) · Analytical Chemistry · doi:10.1021/ac502040v · Cited by 1,263
Self-citationHijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics
Ting, L., Rad, R., Gygi, S. P., & Haas, W. (2011) · Nature Methods · doi:10.1038/nmeth.1714 · Cited by 1,009
Self-citationBharathavikru, S., & Dudnakova, T. (2016) · Cited by 953
Modular PROTAC design for the degradation of oncogenic BCR-ABL
Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618
Revisiting Global Gene Expression Analysis
Lovén, J., Orlando, D. A., Sigova, A. A., Lin, C. Y., Rahl, P. B., Burge, C. B., Levens, D. L., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.10.012 · Cited by 616
Self-citationIncreasing the Multiplexing Capacity of TMTs Using Reporter Ion Isotopologues with Isobaric Masses
McAlister, G. C., Huttlin, E. L., Haas, W., Ting, L., Jedrychowski, M. P., Rogers, J. C., Kuhn, K., Pike, I., Grothe, R. A., Blethrow, J. D., et al. (2012) · Analytical Chemistry · doi:10.1021/ac301572t · Cited by 605
Self-citationQuantitative ChIP-Seq normalization reveals global modulation of the epigenome
Orlando, D. A., Chen, M. W., Brown, V. E., Solanki, S., Choi, Y. J., Olson, E. R., Fritz, C. C., Bradner, J. E., & Guenther, M. G. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.018 · Cited by 503
Self-citationWinter, G. E., Mayer, A., Buckley, D. L., Erb, M. A., Roderick, J. E., Vittori, S., Reyes, J. M., di Iulio, J., Souza, A., Ott, C. J., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.004 · Cited by 465
Self-citationFlavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
Chao, S., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., & Price, D. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000446200 · Cited by 456
Functional Interrogation of the Kinome Using Nucleotide Acyl Phosphates
Patricelli, M. P., Szardenings, A. K., Liyanage, M., Nomanbhoy, T. K., Wu, M., Weissig, H., Aban, A., Chun, D., Tanner, S. W., & Kozarich, J. W. (2006) · Biochemistry · doi:10.1021/bi062142x · Cited by 426
Self-citationYamada, T., Yamaguchi, Y., Inukai, N., Okamoto, S., Mura, T., & Handa, H. (2006) · Molecules and Cells · doi:10.1016/j.molcel.2005.11.024 · Cited by 421
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2166 · Cited by 374
Self-citationIn Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases
Patricelli, M. P., Nomanbhoy, T. K., Wu, J., Brown, H., Zhou, D., Zhang, J., Jagannathan, S., Aban, A., Okerberg, E. S., Herring, C., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.04.011 · Cited by 358
Self-citationWada, T., Takagi, T., Yamaguchi, Y., Watanabe, D., & Handa, H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7395 · Cited by 355
Sanda, T., Lawton, L. N., Barrasa, M. I., Fan, Z. P., Kohlhammer, H., Gutiérrez, A., Ma, W., Tatarek, J., Ahn, Y., Kelliher, M. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.007 · Cited by 343
Self-citationGilchrist, D. A., Nechaev, S., Lee, C., Ghosh, S., Collins, J. B., Li, L., Gilmour, D. S., & Adelman, K. (2008) · Genes & Development · doi:10.1101/gad.1643208 · Cited by 308
Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
Sedlacek, H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A., et al. (1996) · International Journal of Oncology · doi:10.3892/ijo.9.6.1143 · Cited by 275
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
Chen, R., Keating, M. J., Gandhi, V. V., & Plunkett, W. K. (2005) · Blood · doi:10.1182/blood-2005-04-1678 · Cited by 261
Misra, R. N., Xiao, H., Kim, K. S., Lu, S., Han, W.-C., Barbosa, S. A. L., Hunt, J. T., Rawlins, D. B., Shan, W., Ahmed, S. Z., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0305568 · Cited by 258
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinomaPreprint
Huang, C., Lujambio, A., Zuber, J. A., Tschaharganeh, D. F., Doran, M. G., Evans, M. J., Kitzing, T. M., Zhu, N., de Stanchina, E., Sawyers, C. L., et al. (2014) · Genes & Development · doi:10.1101/gad.244368.114 · Cited by 204
The cyclin‐dependent protein kinases and the control of cell division
Dorée, M., & Galas, S. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.14.7958616 · Cited by 203
König, A. A., Schwartz, G. K., Mohammad, R. M., Al-Katib, A. M., & Gabrilove, J. L. (1997) · Blood · doi:10.1182/blood.v90.11.4307 · Cited by 191
Identification of a Cyclin Subunit Required for the Function ofDrosophila P-TEFb
Peng, J., Marshall, N. F., & Price, D. H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13855 · Cited by 178
Poss, Z. C., Ebmeier, C. C., Odell, A. T., Tangpeerachaikul, A., Lee, T., Pelish, H. E., Shair, M. D., Dowell, R. D., Old, W. M., & Taatjes, D. J. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.030 · Cited by 170
Hirose, Y., & Ohkuma, Y. (2007) · The Journal of Biochemistry · doi:10.1093/jb/mvm090 · Cited by 168
Bonhoure, N., Bounova, G., Bernasconi, D., Praz, V., Lammers, F., Canella, D., Willis, I. M., Herr, W., Hernandez, N., Delorenzi, M., et al. (2014) · Genome Research · doi:10.1101/gr.168260.113 · Cited by 155
Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism
Lu, H., Xue, Y., Yu, G. K., Arias, C., Lin, J., Fong, S. K., Faure, M., Weisburd, B., Ji, X., Mercier, A., et al. (2015) · eLife · doi:10.7554/elife.06535 · Cited by 150
Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Kryštof, V., & Uldrijan, S. (2010) · Current Drug Targets · doi:10.2174/138945010790711950 · Cited by 138
The transition from transcriptional initiation to elongation
Wade, J. T., & Struhl, K. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.12.008 · Cited by 117
Chemical inhibition of the TFIIH-associated kinase Cdk7/Kin28 does not impair global mRNA synthesis
Kanin, E. I., Kipp, R. T., Kung, C. K.-H., Slattery, M. G., Viale, A. J., Hahn, S., Shokat, K. M., & Ansari, A. Z. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611505104 · Cited by 111
Edwards, A., & Haas, W. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3341-9_1 · Cited by 87
Self-citationRodríguez‐Molina, J. B., Tseng, S. C., Simonett, S. P., Taunton, J., & Ansari, A. Z. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.036 · Cited by 74
Pctaire1 Phosphorylates N-Ethylmaleimide-sensitive Fusion Protein
Liu, Y., Cheng, K., Gong, K., Fu, A. K. Y., & Ip, N. Y. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513496200 · Cited by 72
PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma
Sun, T., Co, N. N., & Wong, N. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.05.002 · Cited by 49
Mitra, P., Yang, R.-M., Sutton, J. C., Ramsay, R. G., & Gonda, T. J. (2016) · Oncotarget · doi:10.18632/oncotarget.6997 · Cited by 48
Nomanbhoy, T. K., Sharma, G., Brown, H., Wu, J., Aban, A., Vogeti, S., Alemayehu, S., Sykes, M., Rosenblum, J. S., & Kozarich, J. W. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00629 · Cited by 31
Self-citationTBP loading by AF4 through SL1 is the major rate-limiting step in MLL fusion-dependent transcription
Okuda, H., Takahashi, S., Takaori-Kondo, A., & Yokoyama, A. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1222337 · Cited by 26
Samarakkody, A. S., Abbas, A., Scheidegger, A., Warns, J. A., Nnoli, O., Jokinen, B., Zarns, K., Kubat, B., Dhasarathy, A., & Nechaev, S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv263 · Cited by 23
Flagged first, then by citations
Cited by
Sorted by citations
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Self-citationTargeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 830
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652
“The classical “hook effect” for PROTAC degraders (Bondeson et al., 2015; Burslem et al., 2018a; Chan et al., 2018; Farnaby et al., 2019; Lu et al., 2015; Olson et al., 2018; Schiedel et al., 2018; Winter et al., 2017) was not observed for SD-36 at concentrations as high as 10 μM in all the cell lines tested (Figure 2A…”
BackgroundPROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 663
Metadata
- Authors
- Olson, C. M., Jiang, B., Erb, M. A., Liang, Y., Doctor, Z. M., Zhang, Z., Zhang, T., Kwiatkowski, N., Boukhali, M., Green, J. L., Haas, W., Nomanbhoy, T., Fischer, E. S., Young, R. A., Bradner, J. E., Winter, G. E., & Gray, N. S.
- Affiliations
- Harvard University (US)
- California Sea Grant (US)
- Whitehead Institute for Biomedical Research (US)
- Corresponding author
- Gray, Nathanael S
- ORCID
- Venue
- Nature Chemical Biology
- Published
- 2017-12-18
- Volume
- 14
- Issue
- 2
- Pages
- 163-170
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC5912898
- OpenAlex
- W2781383440
- Cited by
- 552
- References
- 49
- Citations by year
- 2026: 41 · 2025: 78 · 2024: 71 · 2023: 63 · 2022: 69 · 2021: 77 · 2020: 77 · 2019: 51 · 2018: 24 · 2017: 1
- FWCI
- 17.42
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion)
- PMC
- Funders
- National Cancer Institute (R01CA179483, R01CA218278)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- CDK9, transcription elongation, CDK9 inhibitor, SNS-032, cereblon, E3 ubiquitin ligase, apoptosis, transcriptional dysregulation, cancer therapy
- MeSH terms
- Humans, Ligands, Oxazoles, Peptide Hydrolases, Phosphorylation, Protein Binding, Protein Conformation, Thalidomide, Thiazoles, Apoptosis, Crystallography, X-Ray, Inhibitory Concentration 50, Proteomics, Cyclin-Dependent Kinase 9, Ubiquitin-Protein Ligases, Cell Line, Tumor, Protein Kinase Inhibitors, Adaptor Proteins, Signal Transducing, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
